key: cord-1005453-nujqk92v
authors: Gutiérrez-Abejón, Eduardo; Martín-García, Débora; Tamayo, Eduardo; Álvarez, F. Javier; Herrera-Gómez, Francisco
title: Clinical Profile, Pharmacological Treatment, and Predictors of Death Among Hospitalized COVID-19 Patients With Acute Kidney Injury: A Population-Based Registry Analysis
date: 2021-06-15
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2021.657977
sha: b781527ae6c547caee20ff0f2b90aefc69f13e66
doc_id: 1005453
cord_uid: nujqk92v

Introduction: One of the worst clinical outcomes of the coronavirus disease 2019 (COVID-19) pandemic was acute kidney injury (AKI). Methods: This manuscript presents results from a population-based registry study assessing treatment, comorbidities, and predictors of hospital death among COVID-19 patients with AKI from March 1st to May 31th, 2020. Death, oxygen delivery and ventilation, acute dialysis need, use of medications, and various clinical outcomes, in addition to the length of stay in the hospital and intensive care unit (ICU), were evaluated. Results: In Castile and Leon, the largest region of Spain, 10.87% of the patients admitted for COVID-19 (n = 7,307) developed AKI. These patients were known by having hypertension (57.93%), cardiovascular disease (48.99%), diabetes (26.7%) and chronic kidney disease (14.36%), and they used antibiotics (90.43%), antimalarials (60.45%), steroids (48.61%), antivirals (33.38%), anti-systemic inflammatory response syndrome (SIRS) drugs (9.45%), and tocilizumab (8.31%). Mortality among patients with AKI doubled that observed in patients without AKI (46.1 vs. 21.79%). Predictors of hospital death in COVID-19 patients with AKI were ventilation needs (OR = 5.9), treatment with steroids (OR = 1.7) or anti-SIRS (OR = 2.4), severe acute respiratory syndrome (SARS) occurrence (OR = 2.8), and SIRS occurrence (OR = 2.5). Conclusions: Acute kidney injury is a frequent and serious complication among COVID-19 patients, with a very high mortality, that requires more attention by treating physicians, when prescribing medications, by looking for manifestations particular to the disease, such as SARS or SIRS.

Acute kidney injury (AKI) continues to affect between 10 and 40% of in-hospital coronavirus disease 2019 (COVID- 19) patients (1) (2) (3) (4) . Since the beginning of the COVID-19 pandemic, mostly elderly individuals with many comorbidities have developed AKI and died (5, 6) . The adaptation of mechanisms to the kidneys that respond to hemodynamic changes, inflammation, and other stress-inducing situations, perform worse in cases of previous kidney affectation, diabetes, heart failure, etc. Furthermore, in COVID-19 patients, systemic inflammatory response syndrome (SIRS) and severe acute respiratory syndrome (SARS) may exhaust kidney function capacities, leading to the appearance of AKI (4) .

Acute kidney injury is a direct result of COVID-19 infection (7) and is common in critically ill patients, being one of the poor clinical outcomes with a negative prognosis for survival (4, 8) .

In addition, AKI incidence and death rates are changing throughout the regions of world, probably in relation to the characteristics of the individuals in those regions. In this sense, we report our pharmacological, clinical, and epidemiological findings related to the in-hospital COVID-19 patients with AKI.

The main aim of this study was to describe the pharmacological treatment and the clinical baselines of the in-hospital COVID-19 patients affected by AKI (March 1st to May 31th, 2020), in Castile and Leon, the largest region of Spain. Furthermore, we have analyzed the risk factors associated with deaths of COVID-19 patients with AKI. Finally, the influence of AKI on the survival of the in-hospital COVID-19 patients was analyzed.

This article presents findings from an epidemiological analysis carried out following a population-based registry study design, with the collection of clinical and administrative data. The Reporting of studies Conducted using Observational Routinelycollected health Data (RECORD) recommendations (9) and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) standards (10) were adhered to. Ethics committee approval reference and date: PI 20-1863, June 11th, 2020. This study evaluated cross-sectionally clinical findings, treatment, and outcomes from a population of COVID-19 patients with AKI. These study participants were selected from the total COVID-19 patient population with a recorded stay in public Castile and Leon hospitals between March 1st and May 31th, 2020. COVID-19 was diagnosed by in-hospital treating physicians who decided on hospitalizing the patients on the basis of clinical or radiological findings defining SARS (Supplementary Table 1) . A positive result on the COVID-19 real-time reverse transcription polymerase chain reaction (rRT-PCR) test for qualitative detection of the nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was not required to formally diagnose the disease. SIRS was diagnosed following the proper criteria (Supplementary Table 1 ) (11) .

Acute kidney injury was diagnosed in the hospital by treating physicians using the Kidney Disease Improving Global Outcomes (KDIGO) criteria (12) and, following these recommendations, by calculating glomerular filtration rate (GFR) with the Modification of Diet in Renal Disease (MDRD) study equation, or the Chronic Kidney Disease EPIdemiology Collaboration (CKD-EPI) equation (Supplementary Table 1) : briefly, an increase in serum creatinine (SCr) by ≥0.3 mg/dL within 48 h or ≥1.5 times within the prior 7 days, in addition to an urine volume <0.5 ml/kg/h for 6 h, was required.

These patients may have chronic kidney disease (CKD), categories 3-5, defined by an estimated GFR of 60 ml/min or lower (13) : the MDRD or CKD-EPI equations were used for following up the kidney function of patients with visits to Nephrology units, and the Cockcroft-Gault formula was used for patients with visits to primary healthcare centers depending on public Castile and Leon hospitals. Dialysis patients were excluded. Cardiovascular disease was defined by the occurrence of major adverse cardiovascular events (MACE), which included all nonfatal coronary events, including revascularization procedures, and all cerebrovascular events, including transient ischemic attacks (TIA). Peripheral artery disease and decompensated heart failure (HF) were considered indicative of cardiovascular disease. Diabetes, hypertension, and other well-known cardiovascular risk factors were also considered.

Access to registries containing EHR information from the Castile and Leon hospitals and associated primary healthcare centers (Jimena and Medora, https://www.saludcastillayleon. es/sanidad/cm), hospital pharmaceutical care information in our region (Concylia, http://www.saludcastillayleon.es/ portalmedicamento/es/indicadoresinformes/concylia) and hospital discharges information in Castile and Leon (Pestadistico, https://pestadistico.inteligenciadegestion.mscbs.es/publicoSNS/ N/rae-cmbd/rae-cmbd), was obtained.

The main outcome during the study period was death (March 1st to May 31th, 2020). Other outcomes were stays in the hospital and intensive care unit (ICU) (length in days), the need for acute dialysis, SARS, SIRS, disseminated intravascular coagulation (DIC), cardiomyopathy, and bacterial and fungal superinfection.

The use of medications to treat COVID-19 according to the Spanish national recommendations (14, 15) (Supplementary Table 2 ) during the study period (i.e., antibiotics, antimalarials, steroids, antivirals, tocilizumab, and other anti-SIRS), was assessed through dispensaries in public hospitals in Castile and Leon. Anatomical Therapeutic Chemical (ATC) classification was used to evaluate medication consumption (Supplementary Table 3 ). Data on the use of oxygen delivery using low-flow systems (nasal cannula and simple face masks) and high-flow systems (high-flow nasal cannula, venturi masks, and rebreather masks), non-invasive pressure positive ventilation (NIPPV), and invasive ventilation (IV), was also assessed. 

Statistical analysis was carried out considering age and gender distributions and an age cut-off at 65 years of age. A 15day period analysis was performed for all measurements and consideration of all clinical outcomes (March 1-14 to May 15-31, 2020). Frequencies (in percentages) and their corresponding 95% confidence intervals (95% CI) and means or medians with, respectively, their standard deviations (SD) or interquartile ranges (IQR), are presented, as appropriate.

Comparisons were performed using the Student t-test or the Mann-Whitney U-test (for continuous variables), after confirmation of normal distribution of data in a given variable (Kolmogorov-Smirnov-test), and using Pearson's chi-square-test or Fisher's exact-test (categorical variables).

Multiple logistic regression, with a forward selection approach, was performed for in-hospital COVID-19 patients with or without AKI, who died, as opposed to those who did not die. The odds ratio (OR) and a 95% CI were presented. The following variables were included in the analysis: age (>65 years), gender, comorbidities (hypertension, diabetes, cardiovascular disease, CKD), obesity (BMI ≥ 30 kg/m 2 ), need for ventilation, acute dialysis need (only in patients developing AKI), medications used (antibiotics, antimalarials, steroids, antivirals, tocilizumab, or anti-SIRS), occurrence of SARS, SIRS, DIC, cardiomyopathy, and bacterial and fungal superinfections. The survival of COVID-19 patients with and without AKI was performed using the Kaplan-Meier approach and the log-ranktest for comparison between groups.

The level of significance was set at p < 0.05. All statistical analyses were performed by using the Statistical Package for the Social Sciences (SPSS) software version 24.0. (SPSS Inc., Chicago, IL).

From a total population of 7,307 in-hospital COVID-19 patients for which data were available, the findings presented here describe 794 patients with AKI (10.87%), most of them males aged 65 years or more. Around half of the patients had hypertension or cardiovascular disease ( Table 1) . Many of these patients also had diabetes mellitus (26.7%) and CKD categories 3-5 (14.36%).

Into the group of COVID-19 patients presenting AKI, there were no differences in comorbidities between the two gender groups. Nevertheless, compared with females, twice as many male patients needed IV and three times as many male patients needed at least one session of acute dialysis, even if NIPPV and oxygen delivery were used similarly by both genders ( Table 1) . Males also had SARS and cardiomyopathy more commonly, and their hospital length of stay (median 10 days) was more prolonged, compared with that of females. In addition to antibiotics, male patients also used more antimalarials, steroids, antivirals, other anti-SIRS, and tocilizumab, compared with females ( Table 1 ).

In addition, within the first 15-day period the mortality rate was very high (75%), while decreasing to 44.12% in the last 15day period. The same trend applies to the length of hospital stay (Figure 1 and Supplementary Table 4) . The peak of AKI incidence was reached between April 15th and May 14th (about 14%). COVID-19 patients with AKI needed to stay in the ICU more frequently in the second half of March 2020 (27.2%) (Supplementary Table 4 ).

While the use of antibiotics and steroids, to some extent, remains stable throughout the time, the use of rest of the medications decreased during the study period (Figure 2 and Supplementary Table 4 ). Table 2 shows the medication received by COVID-19 patients with AKI who died or survived: significantly lower use of antibiotics and greater use of beta interferon (another anti-SIRS drug category) were noted in those who died compared with those patients who did not die.

No impact on survival in patients with or without AKI was observed (median survival: 12 vs. 12 days; p = 0.55) Figure 1) 

This study shows that AKI was present in 1 out of 10 inhospital COVID-19 patients (March 1st to May 31th, 2020) and that 9 out of 10 cases occurred in people aged more than 65 years, with a mortality around 50%. Ventilation, the use of some medications (steroids, anti-SIRS), and SARS and SIRS incidence may be present in COVID-19 patients with AKI who have an increased risk of death. In addition, AKI had no impact on median survival (in days) compared with in-hospital COVID-19 patients who did not develop AKI. However, mortality among patients with AKI was twice that observed in patients without AKI (46.1 vs. 21.79%) (16) , and it is higher than in other studies (17) .

Surprisingly, obesity had no influence on death of the patients both with AKI and without AKI, contrary to other studies (18, 19) . Probably, lower rates of obesity (in patients with or without AKI, 21.16 and 18.58%, respectively) compared with other cohorts, may be an explanation (20) .

Meta-analyses assessing COVID-19 patients from all over the world with AKI confirm that the incidence of AKI was greater in our region compared with Asia (4.3%) but lower than in North America (22.6%) and similar to that of other European countries (11.6%) (3, 8, 21, 22) . Surprisingly, the mortality rate in Castile and Leon, Spain, was higher than in all of them. It is difficult to establish which factors are associated with this high mortality rate, which probably is related to the aging of the population in Castile and Leon, but also to other factors, such as the "collapse" of the Spanish public health system, the limited expertise of physicians in treating COVID-19 patients at such a moment, professional extenuation, etc. In this sense, there were differences with respect to other cohorts having an elevated percentage of patients aged 65 years or older, as in our region, which obliging to define the prognosis of the COVID-19 patient with AKI (21): AKI itself seems to have an impact on death, as demonstrated by our analysis and according to findings in other studies (8, 22) ; however, the impact from other factors should be characterized and considered for different world regions. However, it seems clear that mortality is higher in patients with chronic kidney disease who develop AKI (23) . Our study shows that ventilation, the use of some medicines (steroids, anti-SIRS), the occurrence of SARS or SIRS may depict a patient with a poor prognosis: Physicians should understand that such an individual has an elevated risk of dying, and they should consider these factors in order to assist COVID-19 patients with AKI now and in the future. Importantly, previous clinical conditions, such as age and gender, as well as the need for acute dialysis, seem to have no influence on the change in patients, but the use of some medications (steroids, anti-SIRS) and the severity of COVID-19 (SARS occurrence, signs of SIRS), should lead to more intensive interventions.

This study provides real-world evidence of risk factors associated with the deaths of COVID-19 patients with AKI in the largest region of Spain. As in other healthcare settings (24) , assessing data that come from the actual clinical practice has contributed to the characterization of a population suffering bad outcomes. Nevertheless, questions about the quality of the evidence may arise. The findings presented here may be considered to belong to "emerging sources" from outside classic research environments (25) .

This real-world data study presents a comprehensive analysis from the COVID-19 pandemic in Castile and Leon, the largest region of Spain, with a population of 2,323,770 inhabitants and a network of public hospitals with a total capacity of 7,141 beds (14 hospitals). Our findings thus cover all in-hospital COVID-19 patients (n = 7,307), of whom those presenting with AKI are presented here (n = 794).

This study has limitations that should be mentioned. First, although all extracted COVID-19 cases were recorded in the health administration registries accessed as COVID-19 patients, in one third of the cases, COVID-19 diagnosis was clinical or radiological, without microbiological confirmation, as tests were not available for all and because clinical judgment was the only tool at that time. Therefore, risk of selection bias should invite prudence in interpreting the results of this article. Second, due to the collapse of the health system, errors in the clinical data register during the first COVID-19 wave have been observed, which may explain study attrition. Furthermore, selection bias is suspected in the figures of CKD prevalence as not all CKD patients in KDIGO GFR categories 3-5 return to general practitioners after the first consultation in nephrology departments, and not all patients in those CKD categories are sent by general practitioners to the nephrologist. The Angiotensin-Converting Enzyme Inhibitors (ACE)/Angiotensin II Receptor Antagonists (ARB) ratio could be related to the COVID patients' survival; unfortunately, that information was not available, which may be a limitation. Over 8 months have elapsed since the collection of the data, which may be a limitation; however, AKI is still one of the COVID-19 outcomes with the worst prognosis. Finally, other medications not included in Spanish guidelines (14, 15) were not taken into account in this study.

In conclusion, AKI was observed in one 1 out of 10 COVID-19 patients, and almost half of them died before discharge, which demonstrates a mortality rate higher than that observed in other regions including Spain (3, 4, (26) (27) (28) (29) .

With respect to the pharmacological treatment of these patients, with the exception of antibiotics and steroids, the use of the medications analyzed decreased throughout the study period, either due to their availability or that of other medications not used in our studio. Our study has characterized the subjects hospitalized with COVID-19 and highlighted the use of medicines to treat systemic inflammation, and this situation has not changed up to now.

Lastly, AKI is a serious complication of COVID-19, and it must be taken into account by physicians in order to pay better attention to patients' treatment and to the occurrence of manifestations such as SARS or SIRS associated with a poor prognosis.

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

The studies involving human participants were reviewed and approved by East Valladolid Health Area Ethics Committee (reference: PI 20-1863). 

Acute kidney injury in patients hospitalized with COVID-19

Acute kidney injury in COVID-19 patients: an inner city hospital experience and policy implications

Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak

Management of acute kidney injury in patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The impact of sociodemographic factors, comorbidities and physiologic response on 30-day mortality in COVID-19 patients in metropolitan detroit

Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis

Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: a systematic review and meta-analysis of 40 studies and 24,527 patients

The reporting of studies conducted using observational routinelycollected health data (RECORD) statement

The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis

KDIGO clinical practice guideline for acute kidney injury

Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline

Clinical Management of COVID-19

Available Treatments for the Management of Respiratory Infection by SARS-CoV-2

Clinical profile, treatment and predictors during the first COVID-19 wave: a population-based registry analysis from castile and Leon hospitals

AKI treated with renal replacement therapy in critically ill patients with COVID-19

COVID-19: obesity, deprivation and death

How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis

Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis

Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States

Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH health care systems collaboratory

Real-world evidence-what is it and what can it tell us?

Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study

The authors thank the Gerencia Regional de Salud de Castilla y León for access to JIMENA, MEDORA, and CONCYLIA database.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2021.657977/full#supplementary-material